The previously mentioned phase 2 basket trial in the neoadjuvant setting also has one arm evaluating the efficacy of neoadjuvant tucatinib combined with trastuzumab and pertuzumab in HER-2-positive breast cancer patients (NCT01042379). The gene discussed is ERBB2; the disease is breast cancer.